Importantly, one patient received concurrent bevacizumab during IDH inhibitor treatment, but, likely, this did not confound our results because they exhibited a rise in nrCBV during the course of this study, even though anti-angiogenic therapy response should cause a notable decrease in tumor volume and nrCBV.30 Additionally, overall survival was unable to be tested given the relatively long overall survival of patients with IDH1-mutant gliomas and the only recent usage of IDH inhibitors in patients, which would result in a significant number of censored patients in the present study cohort. Here, IDH1 is linked to neoplasm.